Literature DB >> 21751362

Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.

Tingting Yue1, Katie Partyka, Kevin A Maupin, Mary Hurley, Philip Andrews, Karen Kaul, A James Moser, Herbert Zeh, Randall E Brand, Brian B Haab.   

Abstract

The current best serum marker for pancreatic cancer, CA 19-9, detects a carbohydrate antigen on multiple protein carriers. Better knowledge of the protein carriers of the CA 19-9 antigen in various disease states may lead to improved diagnostic tests. To identify proteins that carry the CA 19-9 antigen, we immunoprecipitated the CA 19-9 antigen from pooled sera and identified the associated proteins using MS. Among the high-confidence identifications, we confirmed the presence of the CA 19-9 antigen on Apolipoprotein B-100 by antibody arrays and Western blot and on kininogen, ARVCF, and Apolipoprotein E by antibody arrays. We characterized the frequency and levels of the CA 19-9 antigen on the four proteins across various patient groups (pancreatic cancer, pancreatitis, and healthy controls) using antibody arrays. Nearly, 10-25% of the subjects showed elevations of the antigen on each protein, but the elevations were not associated with disease state or total CA 19-9 levels. These results contribute to our knowledge of the carrier proteins of an important functional glycan and the rate at which the glycan is displayed. This work also demonstrates a strategy for using the complementary methods of MS and antibody microarrays to identify protein carriers of glycans and assess the diagnostic value of measuring glycans on individual proteins.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21751362      PMCID: PMC3517053          DOI: 10.1002/pmic.201000827

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  28 in total

Review 1.  The case for early detection.

Authors:  Ruth Etzioni; Nicole Urban; Scott Ramsey; Martin McIntosh; Stephen Schwartz; Brian Reid; Jerald Radich; Garnet Anderson; Leland Hartwell
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

Review 2.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

3.  Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer.

Authors:  S Thompson; E Dargan; G A Turner
Journal:  Cancer Lett       Date:  1992-09-14       Impact factor: 8.679

4.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons.

Authors:  J P Kane; D A Hardman; H E Paulus
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

5.  CA19-9 epitope a possible marker for MUC-1/Y protein.

Authors:  J Akagi; E Takai; Y Tamori; K Nakagawa; M Ogawa
Journal:  Int J Oncol       Date:  2001-05       Impact factor: 5.650

6.  Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease.

Authors:  S Thompson; C A Kelly; I D Griffiths; G A Turner
Journal:  Clin Chim Acta       Date:  1989-10-16       Impact factor: 3.786

7.  Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor.

Authors:  Albert Lee; Joel M Chick; Daniel Kolarich; Paul A Haynes; Graham R Robertson; Maria Tsoli; Lucy Jankova; Stephen J Clarke; Nicolle H Packer; Mark S Baker
Journal:  Mol Cell Proteomics       Date:  2010-02-18       Impact factor: 5.911

Review 8.  Plasma lipoproteins: apolipoprotein structure and function.

Authors:  R W Mahley; T L Innerarity; S C Rall; K H Weisgraber
Journal:  J Lipid Res       Date:  1984-12-01       Impact factor: 5.922

9.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.

Authors:  D K Pleskow; H J Berger; J Gyves; E Allen; A McLean; D K Podolsky
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

Review 10.  Recent progress in understanding apolipoprotein B.

Authors:  S G Young
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

View more
  30 in total

Review 1.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  Glycoprotein disease markers and single protein-omics.

Authors:  Kevin Chandler; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-11       Impact factor: 5.911

3.  Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.

Authors:  Katie Partyka; Kevin A Maupin; Randall E Brand; Brian B Haab
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

Review 4.  Proteomics analysis of bodily fluids in pancreatic cancer.

Authors:  Sheng Pan; Teresa A Brentnall; Ru Chen
Journal:  Proteomics       Date:  2015-04-27       Impact factor: 3.984

5.  Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.

Authors:  Matthew C Dallos; Andrew B Eisenberger; Susan E Bates
Journal:  Oncologist       Date:  2019-10-01

6.  The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.

Authors:  Ben Staal; Ying Liu; Daniel Barnett; Peter Hsueh; Zonglin He; ChongFeng Gao; Katie Partyka; Mark W Hurd; Aatur D Singhi; Richard R Drake; Ying Huang; Anirban Maitra; Randall E Brand; Brian B Haab
Journal:  Clin Cancer Res       Date:  2019-01-07       Impact factor: 12.531

7.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 8.  Early diagnosis of pancreatic cancer: challenges and new developments.

Authors:  Sukhwinder Kaur; Michael J Baine; Maneesh Jain; Aaron R Sasson; Surinder K Batra
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

9.  CA 19-9 and pancreatic cancer.

Authors:  Erxi Wu; Shuang Zhou; Kruttika Bhat; Qingyong Ma
Journal:  Clin Adv Hematol Oncol       Date:  2013-01

10.  Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs).

Authors:  Min-Sik Kim; Sarada V Kuppireddy; Sruthi Sakamuri; Mukul Singal; Derese Getnet; H C Harsha; Renu Goel; Lavanya Balakrishnan; Harrys K C Jacob; Manoj K Kashyap; Shantal G Tankala; Anirban Maitra; Christine A Iacobuzio-Donahue; Elizabeth Jaffee; Michael G Goggins; Victor E Velculescu; Ralph H Hruban; Akhilesh Pandey
Journal:  J Proteome Res       Date:  2012-10-11       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.